Cargando…

Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study

We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate pre-proliferative diabetic retinop...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshitari, Toshiyuki, Asaumi, Noriko, Watanabe, Masaru, Kumagai, Ken, Mitamura, Yoshinori
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605323/
https://www.ncbi.nlm.nih.gov/pubmed/19183764
_version_ 1782162841063653376
author Oshitari, Toshiyuki
Asaumi, Noriko
Watanabe, Masaru
Kumagai, Ken
Mitamura, Yoshinori
author_facet Oshitari, Toshiyuki
Asaumi, Noriko
Watanabe, Masaru
Kumagai, Ken
Mitamura, Yoshinori
author_sort Oshitari, Toshiyuki
collection PubMed
description We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate pre-proliferative diabetic retinopathy OU. Because of the rapid progression of the diabetic retinopathy, she received pan-retinal photocoagulation in both eyes. Two weeks before using pioglitazone, her visual acuity was 0.9 OD and 0.7 OS. On October 2007, pioglitazone was prescribed by her internist because of poorly controlled blood glucose level. Two weeks later, her body weight increased, and her face became edematous. Her visual acuity decreased to 0.5 OU, and ophthlamoscopy showed severe DME in both eyes. Two weeks after stopping pioglitazone, her visual acuity improved to 0.8 OD and 0.5 OS, but the DME was still severe in the optical coherence tomographic images. Then, one half the usual dose (25 mg) of spironolactone, a diuretic, was given and her macular edema was resolved. Her final visual acuity improved to 0.9 OD and 0.7 OS. We recommend that when a patient taking pioglitazone complains of decreased vision, the physician should promptly consult an ophthalmologist.
format Text
id pubmed-2605323
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-26053232009-02-01 Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study Oshitari, Toshiyuki Asaumi, Noriko Watanabe, Masaru Kumagai, Ken Mitamura, Yoshinori Vasc Health Risk Manag Case Report We report a case of severe diabetic macular edema (DME) that developed after pioglitazone was used by a patient with proliferative diabetic retinopathy. A 30-year-old woman with poorly controlled type 2 diabetes mellitus visited our clinic in 2004. She had moderate pre-proliferative diabetic retinopathy OU. Because of the rapid progression of the diabetic retinopathy, she received pan-retinal photocoagulation in both eyes. Two weeks before using pioglitazone, her visual acuity was 0.9 OD and 0.7 OS. On October 2007, pioglitazone was prescribed by her internist because of poorly controlled blood glucose level. Two weeks later, her body weight increased, and her face became edematous. Her visual acuity decreased to 0.5 OU, and ophthlamoscopy showed severe DME in both eyes. Two weeks after stopping pioglitazone, her visual acuity improved to 0.8 OD and 0.5 OS, but the DME was still severe in the optical coherence tomographic images. Then, one half the usual dose (25 mg) of spironolactone, a diuretic, was given and her macular edema was resolved. Her final visual acuity improved to 0.9 OD and 0.7 OS. We recommend that when a patient taking pioglitazone complains of decreased vision, the physician should promptly consult an ophthalmologist. Dove Medical Press 2008-10 /pmc/articles/PMC2605323/ /pubmed/19183764 Text en © 2008 Oshitari et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Oshitari, Toshiyuki
Asaumi, Noriko
Watanabe, Masaru
Kumagai, Ken
Mitamura, Yoshinori
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title_full Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title_fullStr Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title_full_unstemmed Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title_short Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
title_sort severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605323/
https://www.ncbi.nlm.nih.gov/pubmed/19183764
work_keys_str_mv AT oshitaritoshiyuki severemacularedemainducedbypioglitazoneinapatientwithdiabeticretinopathyacasestudy
AT asauminoriko severemacularedemainducedbypioglitazoneinapatientwithdiabeticretinopathyacasestudy
AT watanabemasaru severemacularedemainducedbypioglitazoneinapatientwithdiabeticretinopathyacasestudy
AT kumagaiken severemacularedemainducedbypioglitazoneinapatientwithdiabeticretinopathyacasestudy
AT mitamurayoshinori severemacularedemainducedbypioglitazoneinapatientwithdiabeticretinopathyacasestudy